UTAH MEDICAL PRODUCTS INCUTMD财报
Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...
UTMD Q4 2025 Key Financial Metrics
营收
$9.0M
毛利润
$5.3M
营业利润
$2.4M
净利润
$2.6M
毛利率
58.2%
营业利润率
27.0%
净利率
28.4%
同比增长
-1.2%
EPS
$0.80
资金流向
UTAH MEDICAL PRODUCTS INC Q4 2025 财务摘要
UTAH MEDICAL PRODUCTS INC reported revenue of $9.0M (down 1.2% YoY) for Q4 2025, with a net profit of $2.6M (down 11.6% YoY) (28.4% margin). Cost of goods sold was $3.8M, operating expenses totaled $2.8M.
核心财务指标
| 总营收 | $9.0M |
|---|---|
| 净利润 | $2.6M |
| 毛利率 | 58.2% |
| 营业利润率 | 27.0% |
| 报告期 | Q4 2025 |
UTAH MEDICAL PRODUCTS INC 年度营收
UTAH MEDICAL PRODUCTS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $38.5M). Click any linked year to see what changed vs the prior 10-K.
UTAH MEDICAL PRODUCTS INC 季度营收与净利润历史
UTAH MEDICAL PRODUCTS INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $9.0M | -1.2% | $2.6M | 28.4% |
| Q3 2025 | $9.8M | -1.9% | $2.6M | 26.8% |
| Q2 2025 | $10.0M | -4.3% | $3.0M | 30.6% |
| Q1 2025 | $9.7M | -14.4% | $3.0M | 31.3% |
| Q4 2024 | $9.2M | -25.7% | $2.9M | 31.7% |
| Q3 2024 | $10.0M | -20.0% | $3.6M | 35.6% |
| Q2 2024 | $10.4M | -19.2% | $3.5M | 33.2% |
| Q1 2024 | $11.3M | -9.4% | $4.0M | 34.9% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $11.3M | $10.4M | $10.0M | $9.2M | $9.7M | $10.0M | $9.8M | $9.0M |
| 同比增长 | -9.4% | -19.2% | -20.0% | -25.7% | -14.4% | -4.3% | -1.9% | -1.2% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $135.4M | $130.0M | $129.7M | $122.5M | $122.5M | $120.8M | $122.0M | $122.5M |
| 总负债 | $7.7M | $6.0M | $5.5M | $5.1M | $5.5M | $3.3M | $3.7M | $3.3M |
| 股东权益 | $127.7M | $124.1M | $124.2M | $117.4M | $117.0M | $117.5M | $118.3M | $119.3M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $5.3M | $2.8M | $3.9M | $2.9M | $4.5M | $2.9M | $3.9M | $3.5M |